Robert E. Reiter, M.D., M.B.A.

Founder & Chief Medical Advisor

Dr. Robert Reiter is a Professor of Urology and Molecular Biology and Director of the Prostate Cancer Treatment and Research Program at the David Geffen School of Medicine at UCLA.  He is currently the Principal Investigator of UCLA’s SPORE (Specialized Program in Research Excellence) program, a 12 million dollar research grant from the National Cancer Institute to develop new diagnostic and treatment options for men with prostate cancer. As co-developer of ImaginAb’s technology and Chief Medical Advisor, Dr. Reiter helps ensure high clinical impact and relevance by guiding the validation studies for ImaginAb’s clinical imaging pipeline.Dr. Reiter is a prominent figure in prostate cancer research and treatment, and is currently the Director of the Genitourinary Cancer Program in the Jonsson Comprehensive Cancer Center and the Director of Research in the Department of Urology at UCLA.  Dr. Reiter completed his undergraduate studies at Yale University and then went on to study medicine at Stanford University Medical School.

Anna M. Wu, Ph.D.

Founder & Chief Scientific Advisor

Dr. Anna Wu is a Professor in the Department of Molecular and Medical Pharmacology and a Professor in Pathology and Laboratory Medicine at the David Geffen School of Medicine at UCLA. She is also an Adjunct Professor of Molecular Biology at the Beckman Research Institute of the City of Hope in Duarte, CA. Dr. Wu is a respected leader in molecular imaging who currently serves as the Director of the Cancer Molecular Imaging Program in the Jonsson Comprehensive Cancer Center at UCLA. As an acknowledged expert in engineered antibodies for cancer targeting, Dr. Wu’s research is the foundation of ImaginAb’s technology. Dr. Wu’s role as Chief Scientific Advisor for ImaginAb is built on her strong academic foundation, ability to communicate high impact research, and impressive track record for innovation.  Dr. Wu received her A.B. in Biochemical Sciences from Harvard University and a Ph.D. in Molecular Biophysics and Biochemistry from Yale University.

Christian Behrenbruch, Ph.D, M.B.A.

Founder & Chief Executive Officer

Dr. Behrenbruch is a serial entrepreneur with a diverse background in developing and commercializing biotechnology, healthcare IT and medical devices from both the operational & executive perspective.  Dr. Behrenbruch was a Vice President at Siemens Molecular Imaging following the acquisition of Mirada Solutions and CTI Molecular Imaging, where he was responsible for advanced medical imaging research for lifesciences and clinical use. As one of ImaginAb’s founders and Chief Executive Officer, Dr. Behrenbruch has taken responsibility for establishing the initial operations and financing for ImaginAb.  He brings to the team a strong industry track record in medical imaging technology, product development and technology transfer.  Dr. Behrenbruch completed his undergraduate studies at Monash University, received his Ph.D. from the University of Oxford, and received his MBA jointly from New York University and the London School of Economics.